Wang X, et al. - Researchers used the institutional database to analyze the data of HER2-positive invasive breast cancer patients treated with neoadjuvant chemotherapy (NACT) and achieving pathologic complete response (pCR), to determine the incremental benefit of trastuzumab by using univariate and multivariate Cox regressions. Overall, 223 patients were included which were followed-up for a median duration of 67 months. A total of 83 (37.2%) received NACT without trastuzumab and 140 (62.8%) received NACT plus trastuzumab for 1 year. Findings revealed improved relapse-free survival in the trastuzumab group vs the no-trastuzumab group (95.7 vs 87.8%). In multivariate analysis, endocrine therapy and trastuzumab administration were related to decreased risk of relapse. Based on the findings, considering trastuzumab administration as standard treatment for HER2-positive patients who have achieved pCR after NACT alone was recommended.